Iron Supplementation Does Not Worsen Respiratory Health Or Alter The Sputum Microbiome in Cystic Fibrosis

Abstract: Background: Iron supplementation for hypoferremic anemia could potentiate bacterial growth in the cystic fibrosis (CF) lung, but clinical trials testing this hypothesis are lacking.

Methods: Twenty-two adults with CF and hypoferremic anemia participated in a randomized, double-blind, placebo-controlled, crossover trial of ferrous sulfate 325mg daily for 6 weeks. Iron-related hematologic parameters, anthropometric data, sputum iron, Akron Pulmonary Exacerbation Score (PES), and the sputum microbiome were serially assessed. Fixed-effect models were used to describe how ferrous sulfate affected these variables.

Results: Ferrous sulfate increased serum iron by 22.3% and transferrin saturation (TSAT) by 26.8% from baseline (p <0.05) but did not affect hemoglobin, sputum iron, Akron PES, and the sputum microbiome.

Conclusions: Low-dose ferrous sulfate improved hypoferremia without correcting anemia after 6 weeks. We did not observe significant effects on sputum iron, Akron PES, and the sputum microbiome. Although we did not identify untoward health effects of iron supplementation, a larger blinded randomized controlled trial would be needed to fully demonstrate safety.
IRON SUPPLEMENTATION DOES NOT WORSEN RESPIRATORY HEALTH OR ALTER
THE SPUTUM MICROBIOME IN CYSTIC FIBROSIS

Running Head: Iron Supplementation for CF-Related Anemia

Alex H. Gifford, M.D.¹
Diana M. Alexandru, D.O.²
Zhigang Li, Ph.D.³
Dana B. Dorman, R.N., M.S.N.¹
Lisa A. Moulton, R.N.¹
Katherine E. Price, Ph.D.⁴
Thomas H. Hampton, M.S.⁴
Mitchell L. Sogin, Ph.D.⁵
Jonathan B. Zuckerman, M.D.²
H. Worth Parker, M.D.¹
Bruce A. Stanton, Ph.D.⁴
George A. O’Toole, Ph.D.⁴

¹Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
²Division of Pulmonary and Critical Care, Maine Medical Center, Portland, ME 04102
³Biostatistics and Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755
⁴Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755
⁵Josephine Bay Paul Center for Comparative Molecular Biology and Evolution, Marine Biological Laboratory, Woods Hole, MA 02543
Corresponding author: Alex H. Gifford, M.D.

E-mail: Alex.H.Gifford@hitchcock.org; FAX: +1 603-650-0580; Phone: +1 603-650-5533

Clinical Trials Registration Number: ClinicalTrials.gov NCT01755455

Conflict of Interest: Alex H. Gifford, M.D., Diana M. Alexandru, D.O., Zhigang Li, Ph.D., Dana B. Dorman, R.N., M.S.N., Lisa A. Moulton, R.N., Katherine E. Price, Ph.D., Thomas H. Hampton, M.S., Mitchell L. Sogin, Ph.D., Jonathan B. Zuckerman, M.D., H. Worth Parker, M.D., Bruce A. Stanton, Ph.D., and George A. O’Toole, Ph.D., each declare that he/she does not have a personal or financial interest in the subject matter of this manuscript.
ABSTRACT

Background: Iron supplementation for hypoferremic anemia could potentiate bacterial growth in the cystic fibrosis (CF) lung, but clinical trials testing this hypothesis are lacking.

Methods: Twenty-two adults with CF and hypoferremic anemia participated in a randomized, double-blind, placebo-controlled, crossover trial of ferrous sulfate 325mg daily for 6 weeks. Iron-related hematologic parameters, anthropometric data, sputum iron, Akron Pulmonary Exacerbation Score (PES), and the sputum microbiome were serially assessed. Fixed-effect models were used to describe how ferrous sulfate affected these variables.

Results: Ferrous sulfate increased serum iron by 22.3% and transferrin saturation (TSAT) by 26.8% from baseline (p <0.05) but did not affect hemoglobin, sputum iron, Akron PES, and the sputum microbiome.

Conclusions: Low-dose ferrous sulfate improved hypoferremia without correcting anemia after 6 weeks. We did not observe significant effects on sputum iron, Akron PES, and the sputum microbiome. Although we did not identify untoward health effects of iron supplementation, a larger blinded randomized controlled trial would be needed to fully demonstrate safety.
Abbreviation list

CBC = complete blood count
CF = cystic fibrosis
CFPE = cystic fibrosis pulmonary exacerbation
CFRD = cystic fibrosis-related diabetes
CFTR = cystic fibrosis transmembrane conductance regulator
ELISA = enzyme-linked immunosorbent assay
FEV₁% = percent-predicted forced expiratory volume in one second
IL-6 = interleukin-6
IRB = institutional review board
OTU = operational taxonomic unit
P.a. = Pseudomonas aeruginosa
PEG = polyethylene glycol
PES = Pulmonary Exacerbation Score
SDI = Simpson diversity index
sTfR = soluble transferrin receptor
TSAT = transferrin saturation
BACKGROUND

Anemia affects an estimated 10-29% of adult cystic fibrosis (CF) patients (1-3). We (4) and others (2, 3) have observed low circulatory iron stores (hypoferremia) in 23-100% of anemic CF patients, suggesting that iron deficiency may restrict erythropoiesis (5). Nonetheless, accurate assessment of iron status is challenging in CF because serum ferritin (6) and transferrin saturation (TSAT) (7) are often increased and decreased, respectively, by inflammation, leading to overestimation or underestimation of total body iron reserves. In CF, an elevated serum soluble transferrin receptor (sTfR) level reflects hypoferremic anemia (7) and is not influenced by the acute phase response of infective exacerbation (8), but it cannot distinguish between iron-limited erythropoiesis and anemia of chronic disease (9) wherein iron is not mobilized for erythropoiesis (10). Therefore, no single blood test explains the finding of hypoferremia in CF.

However, iron supplementation is warranted for selected patients (11), but this practice is associated with several theoretical concerns. Bacteria in the CF lung require iron for growth and possess mechanisms to obtain this micronutrient from human tissues (12, 13). Iron enhances the formation of Pseudomonas aeruginosa (P.a.) biofilm communities (14) which can be visualized in the sputum of patients (15). In an epithelial co-culture model, ΔF508-CFTR increases iron in airway surface liquid and augments P.a. biofilm growth and antibiotic resistance (16, 17).

Neovascular changes in bronchial arteries may lead to hemoptysis (18), also introducing iron into the airways. These observations prompted us to ask three related questions about oral iron supplementation: 1) does it increase sputum iron?; 2) does it alter bacterial communities (i.e., the microbiome of sputum from the CF lung)?; and 3) compared to placebo, does it increase the frequency of CF pulmonary exacerbation (CFPE)?
That iron supplementation might be harmful in CF is a concern of clinicians who reported the onset of CFPE symptoms in patients following infusion of intravenous iron (19). Ambiguity in the literature about the definition of CF-related anemia and its underlying mechanisms arguably contribute to the use of iron supplements in patients for whom additional iron is unlikely to be beneficial. We conducted this study to more fully understand the clinical ramifications of iron supplementation in CF.

METHODS

Subjects

Adults who were ≥18 years old with CF confirmed by genotype analysis were recruited from the programs at Dartmouth-Hitchcock Medical Center (DHMC) and Maine Medical Center (MMC). They provided written informed consent as part of identical protocols approved by institutional review boards (IRBs) at both sites. Participants were required to have serum transferrin saturation (TSAT) ≤21% and hemoglobin concentration <15.5 gm/dl (men) or <13.6 gm/dl (women) at screening. TSAT ≤21% is below the mean for 20-39 year old Caucasian women in the third National Health and Nutrition Examination Survey (NHANES III) (20). Cutoffs for hemoglobin are below the gender-specific means for 20-29 year old Caucasians in NHANES III (21). All subjects had a history of ≥1 P.a.-positive sputum culture. Exclusion criteria included use of iron-containing vitamins, history of an iron-overload condition or cirrhosis, pregnancy or breastfeeding, and recent visible hemoptysis.

Study Design

This investigation was a randomized, double-blind, placebo-controlled, crossover trial of ferrous sulfate 325mg taken orally once a day for 6 weeks. Subjects were randomized in a 1:1
allocation. A 30-day washout period occurred between arms. Subjects attended follow-up visits at weeks 0, 3, and 6 of each arm. The CONSORT flow chart (Figure 1) further describes subject participation. Treatment adherence was determined by pill counts and asking subjects about remaining pills at each visit. Because constipation is a common problem in CF (22) that could be worsened by iron, study personnel tracked this symptom. Subjects were advised to avoid taking the study drug at the same time as fluoroquinolones, as iron limits their absorption (23).

Systemic antibiotic use was documented at each visit because of its effect on iron homeostasis (24). CFPE was defined by an Akron Pulmonary Exacerbation Score (PES) ≥5 (25).

**Sample Size and Statistical Analyses**

The primary endpoint of this study was the absolute change from baseline in hemoglobin concentration attributed to ferrous sulfate. Ater et al. (26) found that 8 out of 22 CF patients (36%) treated with ferrous sulfate (6 mg/kg/day) experienced a ≥1.0 gm/dl increase in hemoglobin after 4-5 weeks. We calculated that 28 subjects would be needed to observe this endpoint with power of 80% and α = 0.05. Secondary endpoints were absolute changes from baseline attributed to ferrous sulfate and antibiotic use for the following parameters: serum iron, hepcidin-25, TSAT, sputum iron, and incremental and dichotomized PES (< or ≥5 points).

Paired Student’s t-tests were used to compare sputum microbiome parameters. All data were checked for normality (Kolmogorov-Smirnov test) and were otherwise log-transformed. Heterogeneity of the carry-over effects between the two treatment sequences was refuted by permutation test. Fixed-effect models accounted for repeated measurements within subjects and treatment sequence (27). For log-transformed predictor variables, the estimated effect is expressed as percent change relative to baseline. Otherwise, the estimated effect signifies the absolute change from baseline and (standard error) that is explained by each
variable. Multicollinearity disallowed simultaneous inclusion of serum iron and TSAT in the models. Fisher’s exact test was used to compare side effect frequency and adherence between arms. SAS 9.3® (SAS Institute, Inc., Cary, NC) and GraphPad Prism® 5.04 (GraphPad Software, Inc., La Jolla, CA) were used for all analyses. A two-tailed p-value <0.05 was significant.

Diagnostic Testing

Phlebotomy was performed at weeks 0, 3, and 6 of each arm. Complete blood count (CBC), serum iron, TSAT, and reticulocyte count were measured by automated hematology analyzers in the clinical laboratories of DHMC and MMC. FEV_{1}% reflected percentages of predicted normal values (28). Serum hepcidin-25 and erythropoietin (EPO) were determined at Intrinsic LifeSciences (La Jolla, CA) using a competitive enzyme-linked immunosorbent assay (ELISA) (29) and a commercial ELISA (Quantikine® IVD®, R&D Systems, Inc., Minneapolis, MN), respectively. Total sputum iron was measured by inductively coupled plasma-mass spectrometry (ICP-MS) (24, 30) and is expressed as nanograms of iron per mg of sample (ng/mg). The Akron PES was calculated by study personnel at weeks 0, 3, and 6 of each arm using the version published by Kraynack et al. (25)

Sputum Microbiome Analysis

Relative abundance of P.a. was determined by sequencing, and total bacterial diversity was measured by 454 pyrosequencing of the V4-V6 regions of the 16S rRNA gene from genomic DNA isolated from patient sputum samples, as previously described (31). Deep sequencing, bioinformatic quality filtering, and operational taxonomic unit (OTU) assignments were performed, as previously described (31). Bacterial diversity was calculated using Simpson Diversity Index (SDI). Individual reads, taxon assignments, and descriptions of individual
clusters and diversity calculations are accessible on the website Visualization and Analysis of Microbial Population Structures (http://vamps.mbl.edu).

RESULTS

Enrollment and Subject Characteristics

A total of 31 subjects were screened (Figure 1). Of the 26 subjects who met screening criteria, 24 were randomized to receive ferrous sulfate or placebo. During the initial treatment arm, one subject was lost to follow-up, and one subject was excluded due to lung transplant. Data from these two subjects were not analyzed. All 22 remaining subjects (18 at DHMC, 4 at MMC) finished both arms.

Baseline characteristics of the study population are presented in Table 1. Participants were predominantly males in their third decade of life with moderately-severe lung function impairment. Three-quarters of them were homozygous for ΔF508-CFTR. Two-thirds of the cohort had CF-related diabetes (CFRD).

Treatment Adherence and Side Effects

A total of 3 subjects experienced 3 constipation events during ferrous sulfate use. For comparison, 5 such events were observed in 4 subjects during placebo treatment. The relative risk for constipation on ferrous sulfate was no greater than placebo (RR 1.3, 95% CI 0.7-2.3, p = 0.71). Subjects took 914 of 924 ferrous sulfate doses (99%) and 898 of 924 placebo doses (97%). Risk of missing a dose was higher for placebo (RR 1.4, 95% 1.2-1.8, p = 0.02).

Effect of Ferrous Sulfate on Hemoglobin, Reticulocyte Count, and Serum EPO

In this and subsequent statistical models, data are presented as estimated effects followed by standard error in parentheses. Ferrous sulfate insignificantly increased hemoglobin by 0.04
(0.18) gm/dl (p = 0.81). However, the model showed that every kilogram of body weight lost was associated with a drop in hemoglobin of 0.17 gm/dl (p = 0.01). No other parameter predicted hemoglobin variation. Reticulocyte count and serum EPO were also unaffected by ferrous sulfate.

**Effect of Ferrous Sulfate on TSAT and Serum Iron Concentration**

Data for TSAT and serum iron required log-transformation. For TSAT, the estimated treatment effect was an increase of 26.8 (10.6)% from baseline (p = 0.02). For serum iron, the estimated treatment effect was an increase of 22.3 (9.9)% from baseline (p = 0.03). Absolute changes in TSAT and serum iron for ferrous sulfate and placebo are shown in Figure 2.

Antibiotic use, body weight, Akron PES, and sputum iron did not predict TSAT or serum iron variation. In a responder analysis of data from the ferrous sulfate arm, we found no significant difference in hemoglobin between subjects who did and did not achieve a 13.7 µg/dl increase in mean serum iron (Figure 2).

**Effect of Ferrous Sulfate on Sputum Iron Content**

Use of ferrous sulfate and antibiotics did not significantly affect sputum iron variation from baseline (Table 2). The number of sputum samples permitted a power of 68% to detect the 0.281 ng/mg difference in sputum iron. Thus, the study was underpowered for this endpoint.

Each ng/ml increase in serum hepcidin-25 from baseline was associated with a 1.1 (0.4)% increase in sputum iron (p = 0.02). Each mU/ml increase in serum EPO from baseline accounted for a 5.2 (1.9)% elevation in sputum iron (p = 0.01). No other factor in Table 2 predicted sputum iron changes.

**Correlation Between Ferrous Sulfate and Akron PES**
Ferrous sulfate was not associated with incremental (Table 3) or dichotomized (PES ≥5) scores on the Akron instrument. Therefore, short term treatment did not trigger CFPE as defined by this inventory. The power to detect the observed difference in Akron PES between ferrous sulfate and placebo arms was 42%. Controlling for other variables, antibiotic use was associated with a 1.6 (0.7) point increase from baseline PES (p = 0.04). Each ng/ml increase in serum hepcidin-25 was associated with a PES increase of 0.04 (0.01) points (p = 0.006) (Figure 3). In cases where PES was 5 or higher (i.e., CFPE), each ng/ml increase in serum hepcidin-25 was associated with a 0.07 (0.03) point increase in PES (p = 0.03). The fixed-effect model for PES (Table 3) showed that a gain of 1 kg in body weight predicted a decrease of 0.4 ± 0.2 points for PES (p = 0.047).

Correlation Between Ferrous Sulfate and the Sputum Microbiome

Ferrous sulfate did not impact relative abundance of *P.a.* or community diversity within subjects (Figure 4). Given that the standard deviation of *P.a.* fractions (Figure 4A) was 0.37, we would expect to resolve a difference of 0.30 with 80% power and p <0.01 with 21 paired samples. Relative abundance of CF pathogens, including *Stenotrophomonas, Staphylococcus, Haemophilus, Rothia, Achromobacter*, and all other microbes analyzed was similarly unaffected by ferrous sulfate (data not shown). Hierarchical clustering and principal coordinate analyses revealed no dichotomy between subjects based on treatment status (data not shown). These observations are consistent with the finding that iron supplementation does not increase the availability of iron in CF sputum (Table 2).

**DISCUSSION**
This study demonstrated that a low-dose daily iron supplement improved circulatory iron stores but failed to increase hemoglobin after 6 weeks in CF adults with hypoferremic anemia. Sputum iron, risk of CFPE according to the Akron PES, and the sputum microbiome were unaffected by iron supplementation. Moreover, hepcidin-25, the master regulator of iron metabolism, (32) emerged as a predictor of sputum iron and Akron PES.

Iron-deficiency has long been recognized in CF (26, 33). Some authors have used TSAT <15-16%, (2, 7, 26) to define hypoferremia, while others have used a combination of TSAT <16% and serum iron ≤12 µmol/l (34) or serum iron ≤12 µmol/l (4) alone. Herein, we sought to ensure hypoferremia at screening using TSAT ≤21%, the mean value for 20-39 year old Caucasian women in the NHANES III public health survey (20). Also from NHANES III, (20) Caucasian men in this age range had a higher mean TSAT (27%), which is important because most of our subjects were male. Given that the mean TSAT at screening for women and men in our study were 10 ± 4% and 13 ± 5%, respectively, and that subjects had an average age of 32 years, we contend that they were iron deficient compared to the general population and therefore, reasonable candidates for iron supplementation.

Similarly, mean hemoglobin levels for males (13.6 ± 0.9 gm/dl) and females (12.6 ± 0.7 gm/dl) at screening were lower than gender-specific means for 20-29 year old Caucasians in NHANES III (21), a cohort of comparable age and ethnicity. Therefore, in addition to being iron-deficient, subjects in this trial were mildly anemic. Like hypoferremia, CF-related anemia has been defined (1-4, 26) using different hemoglobin cutoffs in cohorts that vary by age and gender. We hope that this study focuses the discussion of hypoferremic anemia in CF.

Despite the biochemical evidence for anemia and hypoferremia in our subjects, ferrous sulfate did not increase hemoglobin. This finding could reflect type II error because we did not
meet the enrollment target of 28 subjects. Non-adherence did not explain this observation. For
dosing convenience and the ability to generate a matching placebo, we used ferrous sulfate, a
preparation that is absorbed less efficiently than other formulations (35), raising the possibility
that hemoglobin did not respond because serum iron was not sufficiently increased. Low gastric
pH enhances absorption of non-heme iron like ferrous sulfate. (36) Gastric acid suppression
used in CF to protect exogenous pancreatic enzymes from proteolysis may have limited iron
uptake (37), and therefore, hemoglobin production in our subjects. We did not use vitamin C to
enhance iron absorption out of concern for reduced adherence to a more complex regimen.
Nonetheless, ferrous sulfate increased serum iron and TSAT by approximately 22% and 27%,
respectively, after 6 weeks, leading us to infer that anemia might persist because iron cannot be
mobilized for erythropoiesis. This conclusion is supported by our findings that reticulocyte
count, a measure of red blood cell production by the bone marrow, (38) and serum
erthropoietin, the salient growth factor for red blood cell precursors, (39) were unaffected by
iron supplementation.

Iron is an essential nutrient for bacteria that chronically infect the lungs of CF patients,
particularly P.a. (40). To ensure that iron did not cause an unintended increase in P.a. or alter
the sputum microbiome, we characterized sputum microbial communities of each patient by deep
sequencing at each time point in the study. Consistent with the lack of increased iron in the
sputum, we saw no change in overall diversity or relative abundance of P.a. or other CF
pathogens as a result of iron supplementation. Goddard et al. (41) have questioned whether
sputum samples are contaminated by oropharyngeal flora, and thus, do not accurately reflect the
lung microbiome. Yet, these authors reported a high concordance between deep sequencing data
from CF lung tissue and clinical sputum cultures. Because we wanted to determine the effect of
ferrous sulfate on the sputum microbiome within the same subjects on serial samples collected in
the same manner, and because we have no reason to think that iron would differentially influence
flora in the upper and lower respiratory tracts, we feel the data in Figure 4 support the conclusion
that oral iron supplementation does not appear to worsen chronic bacterial infection in the CF
lung.

To investigate whether inflammation influenced trends in the iron content of serum and
sputum, we measured serum hepcidin-25, a peptide hormone that reduces enteral iron absorption
and increases iron sequestration within mononuclear cells in response to interleukin-6 (IL-6)
(42, 43). Using serum hepcidin-25 as a biomarker for the severity of inflammation in CF is
justified by our findings in patients evaluated at the onset of and recovery from CFPE that lower
serum hepcidin-25 and IL-6 concentrations were associated with better lung function and higher
serum and lower sputum iron levels (24). Herein, we report for the first time that serum
hepcidin-25 is associated with sputum iron variation in CF (Table 2) and incremental increases in
Akron PES (Figure 3), a tool that objectifies CFPE (25). The correlation between serum
hepcidin-25 and Akron PES establishes a rationale to explore whether the former test can be
used to predict the onset of CFPE.

There are several important limitations to our study. Ferrous sulfate might not have
increased hemoglobin because anemia was mild, thereby reflecting a potential ceiling effect.
The dose of ferrous sulfate was also low, but this was informed by a concern for causing
constipation in a population already at risk for this problem. Because constipation occurred very
rarely, a larger study using a higher ferrous sulfate dose would be needed to assess the safety of
treatment in CF. The power to detect changes in Akron PES was only 42%; therefore, we cannot
definitely state that iron supplementation is not associated with CFPE. Based on the observed
difference and standard deviation in Akron PES under both treatment conditions, we found that 160 subjects would be needed to ensure that CFPE risk was lower for ferrous sulfate with 80% power and p <0.05. For the endpoint of sputum iron, 29 subjects would be required to detect a treatment-related difference with a power of 80% and p <0.05, but only 22 subjects completed this study. Therefore, a larger study would be required to determine whether ferrous sulfate increases sputum iron in CF and/or is associated with CPFE, as defined using the Akron PES.

In summary, this controlled trial of iron supplementation for the hypoferremic anemia of CF asked whether this practice worsened respiratory health, a concern raised by an in-vitro model of chronic P.a. lung infection (16, 17) and one that several authors have recently discussed (11, 19). We found no evidence that 325 mg of ferrous sulfate taken daily for 6 weeks increased sputum iron, increased the relative abundance of P.a. or other CF pathogens, or hastened CFPE onset according to the Akron PES. Nonetheless, a larger blinded randomized controlled trial would be needed to fully demonstrate safety.

AKNOWLEDGEMENTS

Author contributions

AHG was the principal investigator and responsible for all aspects of the investigation including the final content of the manuscript.

JL, KEP, and THH were responsible for statistical analyses, preparation, and review of the manuscript.

DMA, DBD, LAM, JBZ, and HWP were responsible for data collection, preparation, and review of the manuscript.

MLS was responsible for sputum microbiome analyses and review of the manuscript.

BAS was responsible for study design, preparation, and review of the manuscript.
GO was responsible for study design, measurement of sputum iron, preparation, and review of the manuscript.

The authors would like to acknowledge Gordana Olbina, Ph.D., who performed the ELISAs for serum hepcidin-25 and EPO at Intrinsic LifeSciences, LLC, and Brian P. Jackson, Ph.D., Director of the Trace Metal Analysis Core Facility at Dartmouth.

**Funding Sources:** Flatley Foundation of Boston, Massachusetts (GAO, BAS, AHG); NIH P20-GM103413-10 and R01-HL074175-09 (BAS); Cystic Fibrosis Foundation Research Development Program (STANTO07R0); Hitchcock Foundation (GAO); and NIH R01 AI091699 (GAO). Funding sources had no involvement in the design of this study, collection, analysis, and interpretation of data, writing of this manuscript, and publication decisions.

**Figure Legends**

Figure 1. Diagram of enrollment, allocation, follow-up, and analysis of subjects.

Figure 2. Treatment Related Differences in Serum Iron and TSAT. Bars and whiskers denote mean differences from baseline and (standard error), respectively. After 6 weeks, serum iron increased by 13.7 (5.9) µg/dl for ferrous sulfate but fell by 4.2 (5.7) µg/dl for placebo. TSAT increased 4.7 (1.5) % for ferrous sulfate and fell by 1.8 (1.7) % for placebo. * p <0.05 for comparison of ferrous sulfate to placebo.
Figure 3. Relationship Between Akron PES and Serum Hepcidin-25 in CF. The fixed-effect model for serum hepcidin-25 revealed that every ng/ml increase in serum hepcidin-25 above baseline was associated with a 0.04 (0.01) point increase in Akron PES above baseline (p <0.05). 95% confidence intervals for the slope of this relationship intersect PES = 5 at 35 ng/ml and 115 ng/ml for hepcidin-25.

Figure 4. Sputum Microbiome is Unaltered by Iron Supplementation. The CF sputum microbiome is unaltered by iron supplementation. A) Relative abundance of P.a. as calculated by deep sequencing (P.a. reads/Total reads) for sputum samples obtained from 21 subjects while on or off iron supplementation. Sputum from week 6 of Arm 1 and Arm 2 were compared and analyzed for difference by paired Student’s t-test. Each symbol indicates an individual sputum sample. Horizontal line indicates the mean and error bars indicate the standard deviation. There is no significant difference in P.a. relative abundance in subjects on or off iron supplementation (p >0.05). B) Simpson Diversity Index (SDI) for sputum samples obtained while on or off iron supplementation for the same samples and by the same method described in panel A. There is no significant difference in Simpson Diversity index in subjects on or off iron supplementation (p >0.05).
REFERENCES


Figure 2

![Graph showing the absolute change from baseline in serum iron (μg/dl) and TSAT (%) with Placebo and Ferrous Sulfate treatments. The graph indicates a statistically significant difference (*) between the two groups.](Click here to download high resolution image)
Figure 4
Click here to download high resolution image
Table 1. Subject Baseline Characteristics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number ((n))</td>
<td>22</td>
</tr>
<tr>
<td>Age ((\text{years}))</td>
<td>32.1 (13.6)</td>
</tr>
<tr>
<td>Gender ((\text{M / F}))</td>
<td>14 / 8</td>
</tr>
<tr>
<td>FEV1 ((% \text{ predicted}))</td>
<td>56 (21)</td>
</tr>
<tr>
<td>Body weight ((\text{kg}))</td>
<td>63.9 (11.9)</td>
</tr>
<tr>
<td>dF508 heterozygote ((%))</td>
<td>100</td>
</tr>
<tr>
<td>dF508 homozygote ((%))</td>
<td>77</td>
</tr>
<tr>
<td>CF-related diabetes ((%))</td>
<td>68</td>
</tr>
<tr>
<td>Hemoglobin ((\text{gm/dl})^*)</td>
<td>13.6 (0.9) (\text{(men)})</td>
</tr>
<tr>
<td></td>
<td>12.6 (0.7) (\text{(women)})</td>
</tr>
<tr>
<td>Serum iron ((\mu\text{g/dl})^{**})</td>
<td>62 (38) (\text{(men)})</td>
</tr>
<tr>
<td></td>
<td>51 (22) (\text{(women)})</td>
</tr>
<tr>
<td>TSAT ((%)^*)</td>
<td>13 (5) (\text{(men)})</td>
</tr>
<tr>
<td></td>
<td>10 (4) (\text{(women)})</td>
</tr>
<tr>
<td>Serum hepcidin-25 ((\text{ng/ml})^{**})</td>
<td>48.6 (41.9)</td>
</tr>
<tr>
<td>Sputum iron ((\text{ng/mg})^{**;}\dagger)</td>
<td>1.44 (1.0)</td>
</tr>
</tbody>
</table>

Data are presented as mean (standard deviation) unless otherwise noted.

* Measured at screening

** Measured at randomization

† Based on sputum samples collected from 21 of 22 subjects.
Table 2. Fixed-effect Model for Predictors of Change in Sputum Iron from Baseline

<table>
<thead>
<tr>
<th>Effect*</th>
<th>Estimate</th>
<th>S.E.</th>
<th>t-value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>-3.418</td>
<td>1.854</td>
<td>-1.84</td>
<td>0.08</td>
</tr>
<tr>
<td>Drug sequence</td>
<td>0.236</td>
<td>0.248</td>
<td>0.95</td>
<td>0.35</td>
</tr>
<tr>
<td>Period</td>
<td>-0.126</td>
<td>0.181</td>
<td>-0.70</td>
<td>0.49</td>
</tr>
<tr>
<td>Ferrous sulfate</td>
<td>-0.281</td>
<td>0.196</td>
<td>-1.43</td>
<td>0.16</td>
</tr>
<tr>
<td>Antibiotic use</td>
<td>0.054</td>
<td>0.228</td>
<td>0.24</td>
<td>0.81</td>
</tr>
<tr>
<td>FEV$_1$ (% predicted)</td>
<td>-0.017</td>
<td>0.013</td>
<td>-1.30</td>
<td>0.20</td>
</tr>
<tr>
<td>Serum iron (µg/dl)*</td>
<td>0.410</td>
<td>0.251</td>
<td>1.64</td>
<td>0.11</td>
</tr>
<tr>
<td>Serum hepcidin-25 (ng/ml)</td>
<td>0.011</td>
<td>0.004</td>
<td>2.51</td>
<td>0.02</td>
</tr>
<tr>
<td>Akron PES</td>
<td>-0.032</td>
<td>0.041</td>
<td>-0.77</td>
<td>0.45</td>
</tr>
<tr>
<td>Serum EPO (mU/ml)</td>
<td>0.052</td>
<td>0.020</td>
<td>2.66</td>
<td>0.01</td>
</tr>
<tr>
<td>Hemoglobin (gm/dl)</td>
<td>0.082</td>
<td>0.142</td>
<td>0.58</td>
<td>0.57</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>-0.014</td>
<td>0.063</td>
<td>-0.22</td>
<td>0.83</td>
</tr>
</tbody>
</table>

S.E. = standard error  
* Log-transformed prior to introduction into model.
Table 3. Fixed-effect Model for Predictors of Change in Akron PES from Baseline

<table>
<thead>
<tr>
<th>Effect</th>
<th>Estimate</th>
<th>S.E.</th>
<th>t-value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>-1.773</td>
<td>6.554</td>
<td>-0.27</td>
<td>0.79</td>
</tr>
<tr>
<td>Drug sequence</td>
<td>1.459</td>
<td>0.839</td>
<td>1.74</td>
<td>0.10</td>
</tr>
<tr>
<td>Period</td>
<td>-0.365</td>
<td>0.624</td>
<td>-0.58</td>
<td>0.56</td>
</tr>
<tr>
<td>Ferrous sulfate</td>
<td>-0.738</td>
<td>0.684</td>
<td>-1.08</td>
<td>0.29</td>
</tr>
<tr>
<td>Antibiotic use</td>
<td>1.585</td>
<td>0.731</td>
<td>2.17</td>
<td>0.04</td>
</tr>
<tr>
<td>FEV$_1$ (% predicted)</td>
<td>-0.021</td>
<td>0.046</td>
<td>-0.46</td>
<td>0.65</td>
</tr>
<tr>
<td>Serum iron (µg/dl)*</td>
<td>0.995</td>
<td>0.901</td>
<td>1.10</td>
<td>0.28</td>
</tr>
<tr>
<td>Serum hepcidin-25 (ng/ml)</td>
<td>0.042</td>
<td>0.014</td>
<td>2.98</td>
<td>0.006</td>
</tr>
<tr>
<td>Reticulocyte count (%)</td>
<td>0.781</td>
<td>0.975</td>
<td>0.80</td>
<td>0.43</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>-0.424</td>
<td>0.206</td>
<td>-2.06</td>
<td>0.047</td>
</tr>
<tr>
<td>Hemoglobin (gm/dl)</td>
<td>-0.929</td>
<td>0.469</td>
<td>-1.98</td>
<td>0.06</td>
</tr>
<tr>
<td>Sputum iron (ng/mg)*</td>
<td>-0.244</td>
<td>0.499</td>
<td>-0.49</td>
<td>0.63</td>
</tr>
</tbody>
</table>

S.E. = standard error
* Log-transformed prior to introduction into model.